Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$67.2 million.

  • Coherus Oncology's Cash from Investing Activities fell 1524121.62% to -$67.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $377.4 million, marking a year-over-year increase of 4183.81%. This contributed to the annual value of $230.3 million for FY2024, which is 5923.74% up from last year.
  • Coherus Oncology's Cash from Investing Activities amounted to -$67.2 million in Q3 2025, which was down 1524121.62% from $462.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Cash from Investing Activities registered a high of $462.6 million during Q2 2025, and its lowest value of -$285.5 million during Q1 2021.
  • In the last 5 years, Coherus Oncology's Cash from Investing Activities had a median value of $16.0 million in 2021 and averaged $23.6 million.
  • As far as peak fluctuations go, Coherus Oncology's Cash from Investing Activities crashed by 1756553.22% in 2021, and later soared by 1116039.39% in 2023.
  • Quarter analysis of 5 years shows Coherus Oncology's Cash from Investing Activities stood at $107.5 million in 2021, then crashed by 220.85% to -$129.9 million in 2022, then soared by 127.1% to $35.2 million in 2023, then crashed by 101.54% to -$542000.0 in 2024, then plummeted by 12303.51% to -$67.2 million in 2025.
  • Its Cash from Investing Activities stands at -$67.2 million for Q3 2025, versus $462.6 million for Q2 2025 and -$17.5 million for Q1 2025.